董敏,邹彤,杨杰孚

• 1:北京医院国家老年医学中心

摘要(Abstract)：

<正>1心房颤动流行病学心房颤动(房颤)是临床上常见的心律失常之一,发生率随年龄增长而上升,在老年患者中发生比例更高,75岁以上患者发生率可高达10%~([1])。据统计,美国约有230万房颤患者,大多数患者年龄在65岁以上~([2]);欧洲有超过600万的房颤患者,80岁以上患者比例为9%~([3])。我国80岁以上人群,房颤的患病率为7.5%~([4]),且数量仍在日益增加。有研

关键词(KeyWords)： 心房颤动;老年;卒中

Abstract:

Keywords:

基金项目(Foundation): 基金项目:首都临床特色应用研究(Z171100001017203)

作者(Author): 董敏,邹彤,杨杰孚

参考文献(References)：

• [1]Crandall MA,Bradley DJ,Packer DL,et al.Contemporary management of atrial fibrillation:update on anticoagulation and invasive management strategies.Mayo Clin Proc,2009,84(7):643-662.
• [2]Turagam MK,Velagapudi P,Alpert MA.Does exercise cause atrial fibrillation?Int J Cardiol,2015,181:245-246.
• [3]Lip GYH,Brechin CM,Lane DA.The global burden of atrial fibrillation and stroke:a systematic review of the epidemiology of atrial fibrillation in regions outside north America and Europe.Chest,2012,142(6):1489-1498.
• [4]Zhou Z,Hu D.An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of China's mainland.JEpidemiol,2008,18(5):209-216.
• [5]Mitrousi K,Lip GYH,Apostolakis S.Age as a risk factor for stroke in atrial fibrillation patients:implications in thromboprophylaxis in the era of novel oral anticoagulants.J Atr Fibrillation,2013,6(1):783.
• [6]Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.Ann Intern Med,2007,146(12):857-867.
• [7]张澍,杨艳敏,黄从新,等.中国心房颤动患者的卒中预防规范.中华心律失常学杂志,2015,19(3):162-173.
• [8]李莉.迷宫手术治疗瓣膜病心房颤动.中华心血管病杂志,2002,30(4):200-201.
• [9]Hu D,Sun Y.Epidemiology,risk factors for stroke,and management of atrial fibrillation in China.J Am Coll Cardiol,2008,52(10):865-868.
• [10]Lin HJ,Wolf PA,Kelly-Hayes M,et al.Stroke severity in atrial fibillation.The Framingham study.Stroke,1996,27(10):1760-1764.
• [11]孙艺红,胡大一.非瓣膜性心房颤动患者全球抗凝注册研究中国亚组基线数据分析.中华心血管病杂志,2014,42(10):846-850.
• [12]Mant J,Hobbs FD,Fletcher K,et al.Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study,BAFTA):a randomised controlled trial.Lancet,2007,370(9586):493-503.
• [13]Marinigh R,Lip GY,Fiotti N,et al.Age as a risk factor for stroke in atrial fibrillation patients:implications for thromboprophylaxis.J Am Coll Cardiol,2010,56(11):827-837.
• [14]Singer DE,Chang Y,Fang MC,et al.The net clinical benefit of warfarin anticoagulation in atrial fibrillation.Ann Intern Med,2009,151(5):297-305.
• [15]Friberg L,Rosenqvist M,Lip GY.Net clinical benefit of warfarin in patients with atrial fibrillation:A report from the Swedish atrial fibrillation cohort study.Circulation,2012,125(19):2298-2307.
• [16]Camm AJ,Kirchhof P,Lip GY,et al.Guideline for the management of atrial fibrillation:the task force for the management of atrial fibrillation of the European Society of Cardiology(ESC).Eur Heart J,2010,31(19):2369-2429.
• [17]Kirchhof P,Benussi S,Kotecha D,et al.2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Eur Heart J,2016,37(38):2893-2962.
• [18]Sjlander S.Sjlander A.Svensson PJ,et al.Atrial fibrillation patients do not benefit from acetylsalicylic acid.Europace,2014,16(5):631-638.
• [19]Reddy VY,M9bius-Winkler S,,Miller MA,et al.Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation:the ASAP study(ASAplavix feasibility study with Watchman left atrial appendage closure technology).J Am Coll Cardiol,2013,61(25):2551-2556.
• [20]Hirsh J,Bauer KA,Donati MB,et al.Parenteral anticoagulants:American college of chest physicians evidence-based clinical practice guidelines(8th Edition).Chest,2008,133(6 Suppl):141S-159S.
• [21]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRSguideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society.J Am Coll Cardiol,2014,64(21):e1-e76.
• [22]Lip GY,Huber K,Andreotti F,et al.Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting:executive summary-a consensus document of the European Society of Cardiology working group on thrombosis,endorsed by the European Heart Rhythm Association(EHRA)and the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J,2010,31(11):1311-1318.
• [23]老年人心房颤动诊治中国专家建议写作组,中华医学会老年医学分会,中华老年医学杂志编辑委员会.老年人心房颤动诊治中国专家建议(2011).中国实用内科杂志,2012,30(4):894-908.
• [24]马长生.心房颤动抗凝治疗的新观点和新指南.中国循环杂志,2011,26(5):325-327.
• [25]Dlott JS,George RA,Huang X,et al.National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation.Circulation,2014,129(13):1407-1414.
• [26]Nieuwlaat R,Capucci A,Camm AJ,et al.Atrial fibrillation management:a prospective survey in ESC member countries:the Euro Heart Survey on atrial fibrillation.Eur Heart J,2005,26(22):2422-2434.
• [27]Halperin JL,Hankey GJ,Wojdyla DM,et al.Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily,oral,direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation(ROCKET AF).Circulation,2014,130(2):138-146.
• [28]Giugliano RP,Ruff CT,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation.N Engl J Med,2013,369(22):2093-2104.
• [29]Granger CB,Alexander JH,Mc Murray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med,2011,365(11):981-992.
• [30]Connolly SJ,Eikelboom J,Joyner C,et al.Apixaban in patients with atrial fibrillation.N Engl J Med,2011,364(9):806-817.
• [31]Eikelboom JW,Wallentin L,Connolly SJ,et al.Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation:an analysis of the randomized evaluation of long-term anticoagulant therapy(RE-LY)trial.Circulation,2011,123(21):2363-2372.
• [32]Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med,2009,361(12):1139-1151.
• [33]Culebras A.MesséSR.Chaturvedi S,et al.Summary of evidence-based guideline update:prevention of stroke in nonvalvular atrial fibrillation:report of the guideline development subcommittee of the American Academy of Neurology.Neurology,2014,82(8):716-724.
• [34]Diener HC,Aisenberg J,Ansell J,et al.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation:part 2.Eur Heart J,2016,[Epub ahead of print].
• [35]Wittkowsky AK.New oral anticoagulants:a practical guide for guide for clinicians.J Thromb Thrombolysis,2010,29(2):182-191.
• [36]中华医学会心血管病学分会.非瓣膜病心房颤动患者新型口服抗凝药的应用中国专家共识,中华心律失常学杂志,2014,18(5):321-329.
• [37]Biteker M,Baaran,Dogan V,et al.Real-world clinical characteristics and treatment patterns of individuals aged 80 and older with nonvalvular atrial fibrillation:results from the real-life multicenter survey evaluating stroke study.J Am Geriatr Soc,2017,[Epub ahead of print].
• [38]Zielonka A,Tkaczyszyn M,Mende M,et al.Atrial fibrillation in outpatients with stable coronary artery disease:results from the multicenter RECENT study.Pol Arch Med Wewn,2015,125(3):162-171.
• [39]Schmitt J,Duray G,Gersh BJ,et al.Atrial fibrillation in acute myocardial infarction:a systematic review of the incidence,clinical features and prognostic implications.Eur Heart J,2009,30(9):1038-1045.
• [40]van Diepen S,Widimsky P,Lopes RD,et al.Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention:APEX-AMI insights.Circ Cardiovasc Qual Outcomes,2012,5(4):437-444.
• [41]Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHAguideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines:an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention,2011ACCF/AHA guideline for coronary artery bypass graft surgery,2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease,2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction,2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes,and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery.Circulation,2016,134(10):e123-e155.
• [42]Gao F,Zhou YJ,Wang ZJ,et al.Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation.Int J Cardiol,2011,148(1):96-101.
• [43]Gibson CM,Pinto DS,Chi G,et al.Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy.Circulation,2017,135(4):323-333.
• [44]罗羽慧,崔坤,梅霞.高龄冠心病合并房颤患者不同抗栓治疗方案的疗效及安全性研究.重庆医学,2017,46(5):607-608.
• [45]Cavender MA,Gibson CM,Braunwald E,et al.The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2-TIMI 51trial.Eur Heart J Acute Cardiovasc Care,2015,4(5):468-474.
• [46]Del-Carpio Munoz F,Gharacholou SM,Munger TM,et al.Metaanalysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation.Am J Cardiol,2016,117(1):69-75.
• [47]Zimmerman D,Sood MM,Rigatto C,et al.Systematic review and meta-analysis of incidence,prevalence and outcomes of atrial fibrillation in patients on dialysis.Nephrol Dial Transplant,2012,27(10):3816-3822.
• [48]Marinigh R,Lane DA,Lip GY.Severe renal impairment and stroke prevention in atrial fibrillation:implications for thromboprophylaxis and bleeding risk.J Am Coll Cardiol,2011,57(12):1339-1348.
• [49]Shah M,Avgil Tsadok M,Jackevicius CA,et al.Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.Circulation,2014,129(11):1196-1203.
• [50]Bonde AN,Lip GY,Kamper AL,et al.Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease:a nationwide observational cohort study.JAm Coll Cardiol,2014,64(23):2471-2482.
• [51]Lip GY,Lim HS.Atrial fibrillation and stroke prevention.Lancet Neurol,2007,6(11):981-993.
• [52]Hijazi Z,Lindbck J,Alexander JH,et al.The ABC(age,biomarkers,clinical history)stroke risk score:a biomarker-based risk score for predicting stroke in atrial fibrillation.Eur Heart J,2016,37(20):1582-1590.
• [53]Heidbuchel H,Verhamme P,Alings M,et al.European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace,2013,15(5):625-651.
• [54]Nielsen PB,Larsen TB,Skjth F,et al.Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke,mortality,and bleeding:a nationwide cohort study.Circulation,2015,132(6):517-525.